1. von Eschenbach A, Ho R, Murphy GP, et al. American

Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997; 47:261-4.

2. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-6.

3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.

4. Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998;52:444-9.

5. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Surveillance Epidemiology and End Results (SEER) program. Monogr Urol 1998;19:3-19.

6. Labrie J, Candas B, Cusan L, et al. Diagnosis of noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-6.

7. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.

8. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL.

Prostate-specific antigen as a screening test for prostate cancer. Urol Clin North Am 1997;24:299-321.

9. Brawer MK. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. Eur Urol 1996;29 Suppl 2:19-23.

10. Gerber GS, Chodak GW. Value of prostate cancer screen ing. Eur Urol 1993;24:161-5.

11. Denis LJ. To screen or not to screen? Prostate 1992;Suppl

12. Jacobson JO. Can screening for early-stage prostate cancer be rationalized? Hematol Oncol Clin North Am 1996; 10:549-64.

13. Albertsen PC. Screening for prostate cancer is neither appropriate nor cost effective. Urol Clin North Am 1996;23:521-30.

14. Thompson IM, Rounder JB, Teague JL, et al. Impact of routine screening for adenocarcinoma of the prostate on stage distribution. J Urol 1987;137:424-6.

15. Jenson CB, Shahon DB, Wangensteen OH. Evaluation of annual examinations in the detection of cancer. Specific reference to cancer of the gastrointestinal tract, prostate, breast and female reproductive tract. JAMA 1960;174:1783-8.

16. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989;141:1136-8.

17. Gerber GS, Thompson IM, Thisted R, Chodak GW.

Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993;269:61-4.

18. Mueller EJ, Crain TW, Thompson IM, Rodriguez FR. An evaluation of serial digital rectal examinations in screening for prostate cancer. J Urol 1988;140:1445-7.

19. Flanigan RC, Catalona WJ, Richie JP, et al. Accuracy of dig ital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994;152(5 Pt 1): 1506-9.

20. Lee F, Torp-Pedersen S, Littrup PJ, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate-specific antigen. Radiology 1989;170:29-32.

21. Chodak GW, Wald V, Palmer E, et al. Comparison of digi tal rectal examination and transrectal ultrasonography for the diagnosis of prostate cancer. J Urol 1986;135: 951-4.

22. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical practice by ultrasonogra-phy, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52.

23. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274:1445-9.

24. Mettlin C, Lee F, Drago J, Murphy GP, and members of the

American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2,425 men. Cancer 1991;67:2949-58.

25. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostate carcinoma with prostate-specific antigen. J Urol 1992;147:841-5.

26. Labrie F, Dupont A, Suburu R, et al. Serum prostate spe cific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-51.

27. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.

28. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152:1737-40.

29. Benson MC, Whang IA, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992;147:817-21.

30. Seaman E, Whang M, Olsson CA, et al. PSA density

(PSAD): role in patient evaluation and managment. Urol Clin North Am 1993;20(4):653-63.

31. Bazinet M, Mashref AW, Trudel C, et al. Prospective evalu ation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.

32. Catalona WJ, Richie JP, DeKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate-specific antigen density in the early detection of prostatic carcinoma: receiver operating characteristic curves. J Urol 1994;152:2031-6.

33. Brawer MK, Aramburu EAG, Chen GL, et al. The inability of prostate specific antigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostate cancer. J Urol 1993;150:369-73.

34. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.

35. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate-specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristics curves. J Urol 1994;152(part 1);2037-42.

36. Partin AW, Criley SR, Subong EN, et al. Standard versus age-specific antigen reference ranges among men with clinically localized prostate cancer: a pathologic analysis. J Urology 1996;155:1336-9.

37. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics,

1997. CA Cancer J Clin 1997;47:5-27.

38. Oesterling JE, Kumamoto Y, Tsukamoto T, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75:347-53.

39. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996;335:304-10.

40. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal eval uation of prostate-specific antigen in men with and without prostate disease. JAMA 1992;267:2215-20.

41. Smith DS, Catalona WJ. Rate of change in serum prostate-

specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7.

42. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45:591-6.

43. Christensson A, Lilja H. Complex formation between pro tein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.

44. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993; 11:188-91.

45. Prestagiacomo AF, Lilja H, Pettersson K, et al. A compari son of the free fraction of serum prostate-specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996;156:350-4.

46. Bjork T, Bjartell A, Abrahamsson PA, et al. Alpha 1-chy-

motrypsin production in PSA producing cells is common in prostate cancer but rare in benign prostatic hypertrophy. Urology 1994;43:427-34.

47. Smith CR. The results of prostate carcinomas screening in the U.S. as reflected in the Surveillance, Epidemiology, and End Result program. Cancer 1997;80:1835-44.

48. Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999;161:1189-91.

49. Gohagan JK, Prorok PC, Kramer BS, et al. The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. Cancer 1995;75:1869-73.

50. Schroder FHG, Bangma CH. The European randomized study of screening for prostate cancer (ERSPC). Br J Urol 1997;79 Supp:68-71.

51. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38:83-91.

0 0

Post a comment